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Introduction
Statins, hypolipemic drugs, used worldwide to
lower plasma concentrations of cholesterol-carrying
lipoproteins, are able to reduce clinical events linked to
atherosclerosis (1).
The key effect of statin therapy is the inhibition
of hydroxymethyl glutaryl-coenzyme A reductase, the
enzyme catalysing a rate-limiting step in hepatic cho-
lesterol synthesis. Beyond this inhibition, statins also
show pleiotropic effects, defined as all their vascular
and nonvascular effects independent from the
cholesterol reduction (2).
It has been hypothesized that one of the
pleiotropic effects of statins could be the improvement
of bone health due to the interference with bone metab-
olism through various mechanisms: the reduction of
signal proteins regulating osteoclast activity (3) and the
increased expression of bone morphogenetic protein-2
geneintheratbonetissue(4).Thesemechanismscould
represent the rationale for the use of statins in the treat-
ment of osteoporosis, the most common disease of the
bone characterized by an altered balance between bone
formationandresorption.Somestudieshavefoundthat
theriskoffracturesismarkedlyreducedinpeopleusing
statins versus nonusers, (5-8) while other studies found
no differences (9-11).
The aim of our study was to evaluate the modifi-
cations of bone mineraldensity (BMD) after 1 year of
treatment with simvastatin in 28 hypercholesterolemic
postmenopausal women compared with hyperchole-
sterolemic women treated only with the diet.
Patients and methods
Twenty eight consecutive hypercholesterolemic
women referred to theInstitute for Prevention, Tre-
atment and Rehabilitation of Rheumatic and Cardio-
vascular Disease "Ni{ka Banja", all in postmenopausal
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Statins are able to reduce cardiovascular morbidity and mortality mainly through their
hypocholesterolemic effect. Beyond the inhibition of cholesterol synthesis, the identification of
pleiotropicmechanismshas motivated many studies to evaluatetheeffectsof statinuseonbone
mineral density (BMD) modification.
The aim of our study was to evaluate whether simvastatin treatment (20 mg/d) could
modify BMD in hypercholesterolemic women (n=28) after one-year treatment as compared
with a control group treated only with a diet (n=11). The exclusion criteria was current or previ-
ous therapy with statins, bisphosphonates and/or estrogens. The following parameters were de-
termined at the beginning and after one year, and those are: total cholesterol, triglycerides,
HDL-CandLDL-C(Friedewaldequation).TheBMDwasmeasuredatthelumbarspinebydual
energy x-ray absorpiometry (DEXA).
In the simvastatin treated group, BMD showed an insignificant 2,812% increase after 12
months, respectively (0,965+0,111 v 0,992+0,110, P>0,05). The group treated only with
hypolipidic diet demonstrated a 3,45% decrease in BMD (respectively, 1,042+0,181 v
1.006+0,182; P>0,05) after 12 months. Nevertheless, the comparison of average BMD changes
between the two examined groups during one year showed a significant value diference
(-0,027+0,037 v 0,036+0,036; P<0,0006).
As partly suggested by retrospective or observational data, this longitudinal study indi-
cates that simvastatin treatment achieves a beneficial effect on BMD. Acta Medica Medianae
2005;44(2): 61‡65.
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for atherosclerosis, were included in the study. All of
them were affected by primary hypercholesterolemia
diagnosed on the basis of anamnestic, clinical, and
biochemical parameters and previously treated only
with the diet. Eleven hypercholesterolemic women,
with the presence of no more than two risk factors for
atherosclerosis, were also included in the study. The
two groups were matched for age, body mass index
(BMI) and lipid parameters.
We excluded patients with secondary
hyperlipemias,endocrinologicand/orsystemicdisease,
and those previously treated with steroids, hormone
replacement therapy, thiazides, bisphosphonates, calci-
um,vitaminD,andstatins.Moreover,wealsoexcluded
all subjects affected by secondary osteoporosis.
All patients underwent clinical examination.
Thereafter, blood was drawn in the morning after a
12-hour fast. The following parameters were dete-
rmined: triglycerides (enzymatic colorimetric method),
high-density lipoprotein-cholesterol (HDL-C) (enzy-
matic colorimetric method after precipitation with
polyethilenglycole) and LDL-C (Friedewald
equation). Hypercholesterolemic patients with two or
more risk factors other than LDL-C (group 1) were
treated with simvastatin 20 mg; the control group
(group 2) was treated only with American Heart
Association diet step II.
BMD was measured with dual energy x-ray
absorpiometry (DEXA) on the lumbar spine (from the
first to the fourth lumbar vertebra). According to the
World Health Organization (WHO) classification,12
diagnosis of osteopenia or osteoporosis was based on
BMD expressed as T-score; a T-score represents a
patient’s bone density expressed as the number of
standard deviations (SDs) above or below the mean
BMD value for a normal young adult.
BMD,clinicalandlipidparameterswereinitially
determined and after 12 months.
Parameters are reported as mean and SD;
statistical testing of differences in continuous variables
between groups was made by the Student’s unpaired t
test.Ananalysisofvarianceforrepeatedmeasurements
was used to compare the variations from baseline time
and each control visit. Pearson’s correlation
coefficientstestedtherelationshipbetweenclinicaland
biochemical variables.
Results
Table 1 shows the baseline parameters. As requ-
ested by inclusion criteria, patients in the two groups
were matched for age, BMI and BMD. The two groups
werenotmatchedforriskfactorsandlipidparameters.
Table 2 shows the percentages of normal,
osteopenic,andosteoporoticpatientsinthetwogroups
Table 3 shows BMD and lipid parameters at
baseline and after 12 months. As expected, the group
treated with simvastatin showed a decrease of total
cholesterol and LDL-C significantly higher than group
2. In group 1, BMD showed a nonsignificant increase
after 12 months (P>0,05). In fact, there was an increase
of 2,812%. Group 2, treated only with the hypolipidic
diet, demonstrated a decrease in BMD after 12 months
(-3,45%; P>0,05).
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Table 1. Basal Characteristics of Simvastatin Group (group 1) and Controls (group 2)
Simvastatin Group (n=28) Controls (n=11) P
Age 61,786+6,27 62,11+5,01 NS
Weight 66,5+6,497 66,25+6,13 NS
BMI 25,25+2,87 26,73+2,04 NS
BMD 0,965+0,111 1,042+0,181 NS
T CHOL 8,083+1,740 6,598+1,084 <0,005
TG 1,751+0,656 1,723+0,584 NS
HDL-C 1,168+0,235 1,224+0,239 NS
LDL-C 6,119+1,736 4,591+0,992 <0,001
Table 2. T-Score in Study Population
WHO classification Simvastatin Group Controls
Normal T-score >-1 2 (7,14%) 4 (36,36%)
Osteopenia T-score from -1 to -2,5 18 (64,29%) 5 (45,46%)
Osteoporosis T-score <-2,5 8 (28,57%) 2 (18,18%)Comparison of average BMD changes betwen
the two examined groups during one year (Table 4)
showed significant diference (-0,027+0,037 v
0,036+0,036; P<0,0006). Moreover, we did not find
any significant correlations between changes (the last
determination minus the basal one) of BMD versus
changes in LDL-C (respectively, r= -0.080; P= 0,686.;
r= 0,166, P=0,626) and total cholesterol (respectively,
r=-0.144; P=0,476; r=-0.125.; P=0,715) in group I. No
patients were excluded during the follow up; we did
not observe any clinical or hematochemical adverse
effect of statins. During the 1-year follow-up, patients
did not report any fractures.
Discussion
The present study demonstrated an increase in
BMDinpostmenopausalhypercholesterolemicwomen
treated with simvastatin compared with those treated
only with the diet, who had a trend towards losing
BMD. Our study is a longitudinal study specifically ad-
dressed to examining BMD in hypercholesterolemic
women treated with simvastatin or diet for 1 year.
Moreover, the two groups were also matched for risk
factors, which can influence mineral density, such as
smoking, BMI, and menopausal age.
In the past years, retrospective studies have
indicated a possible beneficial effect of statins on bone
metabolism, but all these studies were not specifically
aimed at examining the drug effect on mineral density.
Infact,mostofthemexaminedtherelationshipexisting
between statin administration and the risk of fracture,
with no univocal results (5-11). Nevertheless, another
study had claimed that the lower incidence of fractures
among statin users could be explained by the higher
bone mass observed in subjects with higher LDL-C
levels (13). However, our studied groups were both
hypercholesterolemic with comparable baseline bone
mineral densities, thus removing this confounder.
Other investigators, who specifically investi-
gated whether statins can increase mineral density,
have suggested that this class of drugs may exert this
positive action; in a retrospective study the use of
statins in diabetic patients reduces the bone loss in
males (14); in a cohort study comparing BMD in statin
users versus nonusers, a higher BMD has been ob-
served among the first group (15); in a third study, the
1-year effect of fluvastatin and pravastatin on BMD
wasmeasured;fluvastatintherapymaintainedBMDaf-
ter 1 year (16). A recent longitudinal study of the
one-year follow-up found a similar beneficial effect of
simvastatin in a group of hypercholesterolemic
postmenopausal women compared with a normo-
lipemic group (17). Another recent cross-sectional
study indicated that statins modulate bone cell func-
tion with an antiresorptive effect (18).
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Table 3. Bone Mineral Density and Lipid Profile During Study Follow up in Study Population
Simvastatin Group (group 1) Controls (group 2)
baseline 12 months Percent of
change (%)
baseline 12 months Percent of
change (%)
Mean+ Standard Deviation Mean+ Standard Deviation
BMD 0,965+0,111 0,992+0,110 2,812 1,042+0,181 1,006+0,182 -3,45
T CHOL 8,083+1,740 7,058+1,139** -12,681 6,598+1,084 6,639+0,612 0,62
TG 1,751+0,656 1,863+0,906 6,362 1,723+0,584 2,008+0,607 16,54
HDL-C 1,168+0,235 1,194+0,273 2,222 1,224+0,239 1,145+0,261 -6,45
LDL-C 6,119+1,736 5,017+1,114† -17,994 4,591+0,992 4,582+0,691 -0,19
*P <0,05 v basal value, **P <0,01 v basal value, †P <0,005 v basal value.
Table 4. Differences between average changes in bone mineral density during follow- up
Simvastatin Group Controls
P value
Mean SD Mean SD
BMD -0,027 0,037 0,036 0,036 0,0006*
T CHOL 1,025 1,273 -0,041 0,995 0,011*
TG -0,111 0,833 -0,285 0,406 0,389
HDL-C -0,026 0,311 0,080 0,277 0,313
LDL-C 1,101 1,271 0,090 0,843 0,004*The link between statins and bone metabolism
lies in several mechanisms. At first, the inhibition of
mevalonate synthesis prevents the synthesis of
isoprenoids, such as farnesylpyrophosphate and gera-
nylgeranylpyrophosphate, which are used by osteo-
claststomodifyandactivateintracellularproteins,such
as glutamyl transpeptidases, as Ras and Rho; the inhi-
bition of prenylation alters osteoclast activity (3,19).
The second mechanism explains how statins have a
biologic activity also on osteoblast activity: Mundy et
al4 demonstrated that statins increase gene expression
of bone morphogenetic protein-2, a protein capable of
increasing osteoblast maturation and bone formation.
The anti-inflammatory effect of statins could be the
third mechanism involved in protection from
osteoporosis. In fact, inflammation, as evident in
rheumatic disorders, is a main determinant of
osteoporosis (20), and in the postmenopausal age there
is an increase in inflammatory cytokines (21); statins
may attenuate such influence by their the well-known
anti-inflammatory effect (22).
In conclusion, this study, indicating a gain in
BMD after 1-year simvastatin treatment, is consistent
with previous observational and retrospective studies
demonstrating a positive influence of statins on bone
formation; these observations and results need to be
supported by larger longitudinal studies specifically
addressed to evaluate the possible role of statin
treatment in osteoporosis.
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EFEKTI STATINSKE TERAPIJE NA KO[TANU GUSTINU
POSTMENOPAUZALNIH @ENA SA
HIPERHOLESTEROLEMIJOM
Dimitrije Jankovi}, Todorka Savi}, Irena Jankovi}, Dejan Spiroski i Bojan Pe{i}
Statini,uglavnomkrozsvoj hipolipemijskiefekat,redukujukardiovaskularnimorbiditet
i mortalitet. Pored inhibicije sinteze holesterola, identifikacija pleotropnih mehanizama
postakla je istra`ivanje efekata upotrebe statina na promenu ko{tane gustine (BMD).
Ciljna{egistra`ivanjabiojedaprocenidaliterapijasimvastatinom(20mg/dan)mo`eda
promeniBMDkodhiperholesterolemi~nih `ena(n=28)nakonjednogodi{njeterapije,kaoikod
kontrolne grupe tretirane samo dijetom (n=11). Aktuelna ili prethodna terapija statinima,
bifosfonatima i/ili estrogenima bila je kriterijum za isklju~ivanje iz studije. Ukupni holesterol,
trigliceridi, HDL-C i LDL-C (po Fridewald-ovoj formuli) su odre|ivani na po~etku i nakon
godinu dana, a BMD je merena na lumbalnoj ki~mi dvostruko energetskom Z-zra~nom
apsorpsciometriom (DEXA).
U grupi tretiranoj simvastatinom, BMD pokazuje nesignifikantno pove}anje od 2,812%
nakon 12 meseci (0,965±0,111 v 0,992±0,110, P>0,05). Grupa tretirana samo
hipolipidemijskom dijetom pokazala je nakon 12 meseci smanjenje BMD od 3,45%
(1,042±0,181 v 1,006±0,182; P>0,05). Pored toga, komparacija prose~ne promene BMD
izme|u ispitivanih grupa u toku jedne godine pokazuje signifikantnu razliku.
Kao {to i delom sugeri{u retrospektivni i opservacioni podaci, ova longitudinalna studija
pokazuje da terapija simvastatinom ima beneficijalne efekte na ko{tanu gustinu. Acta Medica
Medianae 2005;44(2): 61‡65.
Klju~nere~i:simvastatin,ko{tanagustina,hiperholesterolemia,postmenopauzalne`ene